ClinicalTrials.gg
Not yet recruitingNCT07941310Updated Nov 17, 2026

A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer

A Phase 2 interventional study of Bevacizumab and erlotinib in Metastatic Colorectal Cancer and EGFR Amplified Colorectal Cancer, sponsored by Korea University Anam Hospital. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Korea University Anam Hospital · Phase 2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

This phase II, open-label, single-arm clinical trial is designed to evaluate the efficacy and safety of a combination therapy with bevacizumab and erlotinib as a salvage treatment in patients with metastatic colorectal cancer who have failed or are intolerant to standard oxaliplatin- and irinotecan-based chemotherapy, and whose tumors harbor an EGFR copy number gain of 4 or higher confirmed by NGS testing. The primary objective is to evaluate progression-free survival (PFS), and secondary objectives include objective response rate (ORR), overall survival (OS), disease control rate (DCR), safety, and quality of life.

Read the detailed description

This study investigates the clinical benefit of combining an anti-VEGF agent (bevacizumab) with an EGFR tyrosine kinase inhibitor (erlotinib) in refractory metastatic colorectal cancer with EGFR amplification. Eligible patients will receive bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral erlotinib at 150 mg. Tumor assessments will be conducted periodically using RECIST version 1.1 to determine clinical outcomes, and toxicities will be graded according to NCI CTCAE version 5.0.

02

Conditions studied

  • Metastatic Colorectal Cancer
  • EGFR Amplified Colorectal Cancer

Keywords

  • Colorectal cancer
  • EGFR amplification
  • Bevacizumab
  • Erlotinib
  • Salvage therapy
  • Phase 2
03

In context

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

This study's planned enrollment of 39 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Korea University Anam Hospital is the lead sponsor of 114 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically proven /recurrent colorectal cancer who have failed or are intolerant to standard chemotherapy based on oxaliplatin and irinotecan (and if RAS wild-type, an anti-EGFR therapy).
  2. EGFR copy number gain ≥ 4 confirmed by NGS testing performed at the participating institution.
  3. per version 1.1 (measurable lesions are not mandatory for study entry).
  4. Age ≥ 19 years.
  5. performance status 0-2.
  6. Adequate bone marrow and organ function:

    • (ANC) ≥ 1.0 x 10\^9/L
    • (Hgb) ≥ 9.0 g/dL
    • count ≥ 75 x 10\^9/L
    • Serum creatinine ≤ 1.5 x or > 30 mL/min
    • Total ≤ 2.0 x ULN (subjects with biliary obstruction are eligible if criteria are met after appropriate biliary drainage)
    • and ALT ≤ 3 x ULN (or ≤ 5 x ULN if liver metastases are present)
  7. Adequate cardiac function: ≤ 480 msec (if QTc > 480 msec, average QTc \< 480 msec in triplicate measurements).
  8. Ability to swallow oral medication.
  9. Negative serum β-HCG pregnancy test within 14 days prior to study drug administration for female patients of .
  10. Agreement to use appropriate methods as outlined in the protocol.
  11. ≥ 3 months.
  12. Signed and dated prior to any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Prior history of combination therapy with an EGFR tyrosine kinase inhibitor and anti-VEGF blockade.
  3. Known to the study drug components.
  4. Cytotoxic chemotherapy within 14 days, drugs within 2 weeks or 5 half-lives, or monoclonal antibody therapy within 4 weeks prior to study entry.
  5. Uncontrolled severe infection.
  6. Severe medical or psychiatric conditions including active cardiac disease, uncontrolled hypertension, significant arrhythmias, or conditions prolonging .
  7. Active central nervous system (CNS) (unless radiologically stable, asymptomatic, and off for at least 4 weeks; is excluded).
  8. History of another primary (except adequately treated non-melanoma skin cancer, superficial cervical carcinoma, stage 1 bladder cancer, completely resected thyroid cancer, or other solid tumors with no evidence of recurrence for at least 36 months).
  9. Persistence of toxicities from prior anticancer therapy > Grade 1 (except alopecia).
  10. Extensive radiotherapy to the bone marrow within 4 weeks or limited radiotherapy within 2 weeks prior to study entry.
  11. Major surgery within 4 weeks prior to study entry or unrecovered from surgical side effects.
  12. Thrombotic or thromboembolic events within 6 months.
  13. History or evidence of bleeding disorders.
  14. Therapeutic use of maximum dose anticoagulants.
  15. Unhealed wounds, acute ulcers, or bone fractures.
  16. Abdominal fistula, gastrointestinal perforation, or active GI bleeding within 6 months.
  17. Urine dipstick protein ≥ 2+ with 24-hour urine protein > 1g.
  18. History or pathological findings of major GI surgery that may impair oral absorption.
  19. Evidence of active infection including , , or (subjects with controlled or inactive HBV/HCV under specific protocol criteria are permitted).
  20. Conditions or diseases deemed by the investigator to contraindicate study participation.
  21. Medical, psychological, cognitive, or other conditions that impair the subject's ability to understand, consent, or comply with protocol procedures.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Bevacizumab plus Erlotinib

    Participants will receive Bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral Erlotinib at 150 mg.

    Drug: Bevacizumab · Drug: erlotinib

Interventions

  • DrugBevacizumab

    Administered at 7.5 mg/kg intravenously every 3 weeks.

    Also known as: Onbevzi

  • Drugerlotinib

    Administered at 150 mg orally daily.

    Also known as: Eltinib

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is calculated from the date of the first administration of the study drug to the date of documented disease progression or death from any cause.

    Time frame: From the first dose of study treatment until disease progression or death, assessed up to 12 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    Proportion of patients who achieve a Complete Response (CR) or Partial Response (PR) evaluated using RECIST version 1.1.

    Time frame: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

  2. Overall Survival (OS)

    OS is calculated from the date of the first administration of the study drug to the date of death from any cause or the last follow-up date

    Time frame: From the first dose of study treatment until death, assessed up to 1 year of survival follow-up

  3. Disease Control Rate (DCR)

    Proportion of patients who achieve CR, PR, or stable disease (SD) maintained for at least 6 weeks after study drug administration

    Time frame: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

  4. Duration of Response (DOR)

    Calculated from the time initial response (CR or PR) is documented until the date of progressive disease

    Time frame: From initial response until documented disease progression, assessed up to approximately 12 months

  5. Time to Response (TTR)

    Calculated from the first dose of study treatment to the date of initial response (CR or PR)

    Time frame: From the first dose of study treatment until the first documented response, assessed up to approximately 12 months

  6. Safety and Tolerability

    Evaluated by type, frequency, and severity of adverse events graded according to NCI CTCAE version 5.0

    Time frame: From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months

  7. Quality of Life (QoL) EORTC QLQ-C30

    Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    Time frame: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

  8. Quality of Life (QoL) CR26

    Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (CR26)

    Time frame: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Yes. De-identified individual participant data underlying the results reported in this article, after de-identification, will be shared beginning 3 months and ending 5 years following article publication to researchers who provide a methodologically sound proposal. Proposals should be directed to the corresponding author. Data getters will be required to sign a data access agreement.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 3 months and ending 5 years following article publication.

Access criteria: De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal to achieve the aims of the approved proposal. Proposals should be directed to the corresponding author. Data requesters will be required to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Of 498 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 75. This study's planned 12 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Jan 4, 2027
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941310
Responsible party
Lee, Soo Hyeon (Professor, Korea University Anam Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 4, 2027 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Soohyeon Lee, MD, PhD
Contact
soohyeon_lee@korea.ac.kr

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion